Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Oct;117(3):603-9.
doi: 10.1007/s10549-009-0332-2. Epub 2009 Feb 12.

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Stephanie L Hines  1 , Betty Mincey, Todor Dentchev, Jeff A Sloan, Edith A Perez, David B Johnson, Paul L Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Miroslaw A Mazurczak, Daniel A Nikcevich, Charles L Loprinzi
Affiliations
Clinical Trial

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Stephanie L Hines et al. Breast Cancer Res Treat. 2009 Oct.

Abstract

Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized to upfront or delayed zoledronic acid 4 mg every 6 months. Patients in the delayed arm were only given zoledronic acid if they developed a post-baseline BMD T score <-2.0 or had a fracture. The primary endpoint was the mean percent change in lumbar spine (LS) BMD at 1 year. About 558 women enrolled; 395 provided 1 year BMD data. The upfront arm experienced a mean change of +3.66% in LS BMD versus -1.66% for the delayed group (P < 0.001). Changes at the femoral neck/total hip were also greater for the upfront versus delayed arms (P < 0.001; P < 0.001) with differences persisting at 2 years. Patients in the delayed arm were more likely to experience a clinically meaningful 5% loss of BMD at all sites versus the upfront zoledronate group. Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient enrollment diagram
See this image and copyright information in PMC

References

    1. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology. 2006;20(9):1029–1039. - PMC - PubMed
    1. Powles T, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84. - PubMed
    1. The ATAC Trialists’ Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer. 2003;98(9):1802–1810. doi:10.1002/cncr.11745. - PubMed
    1. The ATAC Trialists’ Group Results of the ATAC trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. doi:10.1016/S0140-6736(04)17666-6. - PubMed
    1. Goss PE, Ingle JN, Martino S, Robert JN, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(39):1793–1802. doi:10.1056/NEJMoa032312. - PubMed

Publication types

MeSH terms